Talk Bio

Arrowhead's plozasiran (ARO-APOC3) has delivered highly promising clinical data in severe hypertriglyceridemia (sHTG), with median triglyceride reductions of about 80% and deep suppression of cardiovascular‑risk lipids such as remnant cholesterol and non‑HDL‑C across long‑term and Phase 3 studies. In SHASTA‑3 and SHASTA‑4, 25 mg plozasiran given every three months reduced median triglycerides by 79–81% at 12 months versus placebo and significantly cut the rate of acute pancreatitis events, especially in the highest‑risk sHTG patients. Long‑term data from a two‑year open‑label extension show sustained effects, with 96% of sHTG patients reaching triglycerides below 500 mg/dL and a clean safety profile, positioning Arrowhead as a strong competitor to Ionis in the hypertriglyceridemia space. Sources: Arrowhead Pharmaceuticals Presents New Long-Term Efficacy ... Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients w...